VAC 1

Drug Profile

VAC 1

Alternative Names: Antigen-presenting autologous dendritic cells - Asterias Biotherapeutics; AST-VAC1; Cancer vaccine - Argos/Geron; GRNVAC 1; hTERT RNA vaccine - Argos/Geron; RNA-loaded autologous dendritic cell vaccine - Argos/Geron; VAC1

Latest Information Update: 12 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc; Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 28 Mar 2017 Asterias Biotherapeutics has patent protection for VAC 1 in South Korea, Israel, Singapore and other jurisdictions (Asterias Biotherapeutics form 10-k, March 2017)
  • 04 Oct 2016 Immunomic Therapeutics in-licenses NTC’s RNA-OUT™ and HyperGro™ technology from Nature Technology Corporation
  • 27 Sep 2016 Asterias Biotherapeutics plans a confirmatory phase IIb trial for VAC 1 in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top